Cosmetic peptide interface from simulation and nanoimaging by xirrus simulation, @ xirrus GmbH


Biointerfaces International 2021 Conference will be a hybrid event, comprising both an in-person conference and a virtual conference. The event will gather top-notch academic and industrial experts to discuss latest research findings and future trends.

The format offers delegates attendence in person or access wherever they are in the world. The speakers and the organizing team are looking forward to a dynamic and fruitful exchange. 

Whether you plant to attend in person or if you are not able to travel: Please look for the online registration to open in soon.



Biological surfaces and interfaces: where synthetic materials and biological systems interact with and engage each other - one of the most innovative and expanding areas of science and technology over the last two decades.

Biointerfaces International 2021 Conference follows a special format: Programming aims to build bridges across relevant application areas, between science & engineering, innovation & technology, industry and academic partners and between senior scientists & early-career researchers. Both internationally highly renowned and young scientists from academia, industry and clinics present their latest, often unpublished scientific findings and technological breakthroughs to a diverse audience.

An additional conference focus is education across the many fields of relevance to biological surfaces and interfaces. All conference speakers begin their talks with a general introduction to challenges and strategies that does not require specialized knowledge to follow. Moreover, the Biointerfaces International Seminar 2021 taking place the day before the conference starts (August 16, 2021) covers educational lectures on science, technology and translation to application by speakers both internationally renowned and respected for their contributions to both science, education, translation and outreach to society.




Confirmed Speakers

Morgan Alexander
The University of Nottingham, UK

Madhu Lal-Nag (tbc) 
U.S. Food and Drug Administration FDA, US

Hatice Altug
EPF Lausanne, CH

Shulamit Levenberg 
Technion, Israel Institute of Technology, IL

Jan de Boer (tbc)
University of Eindhoven, NL

Pavel Levkin 
Karlsruhe Institute of Technology KIT, DE

Catarina Brito
iBet - Inst. de Biologia Experimental e Tecnológica, PT

Peter Loskill 
Fraunhofer Inst. for Interfacial Engineering and Biotechnology IGB, DE

Jason A. Burdick
University of Pennsylvania, US

Matthias Lutolf
EPF Lausanne, CH

Patricia Dankers
Eindhoven University of Technology, NL

Ivan Martin
University Basel, CH

Jennifer Elisseeff (tbc) 
Johns Hopkins University, US

Michiya Matsusaki (tbc) 
Osaka University, JP

Bettina Ernst 
Swiss Biotech Association, CH

Sally McArthur
Swinburne University of Technology, AU

Silvia Frey 
Animalfree Research, CH

Tamer Mohamed
Aspect Biosystems, CA

Jianping Fu 
University of Michigan, US

Thorsten Ochsenreiter
University of Berne, CH

Andrés J. Garcia
Georgia Institute of Technology, US

Núria Montserrat Pulido 
Institute for Bioengineering of Catalonia, ES

David W. Grainger
University of Utah, US

Kathy Riklin
Swiss Competence Centre 3R, CH

Michelle Grandin
Alfred E. Mann Institute, US

Melanie Röthlisberger
University of Zurich, CH

Jochen Guck 
Max Planck Inst. for the Science of Light, DE

Adrian Roth 
Roche Innovation Center, CH

Eliav Haskal
NCCR Bio-Inspired Materials, University of Fribourg, CH

Heinz Ruffner 
Novartis, CH

Sarah Heilshorn 
Stanford University, US

Francesca Santoro 
Istituto Italiano di Tecnologia, IT

Sylke Hoehnel
SUN bioscience SA, CH

Romana Schirhagl 
University of Groningen, NL

Reyk Horland
TissUse GmbH, DE

Gerald Schwank
University of Zurich, CH

Rob Howes 
AstraZeneca, UK

Tatiana Segura
Duke University, US

Jian Ji   
Zhejiang University, CN

Benjamin Simona
Ectica Technologies AG

Jens M. Kelm 
PreComb Therapeutics AG, CH

Martina Stenzel 
University of New South Wales, AU

Rama Khokha 
University of Toronto, CA

Mark Tibbitt 
ETH Zurich, CH 

Armin Knoll 
IBM Research, CH

Albert van den Berg (tbc) 
University of Twente, NL

Sarah Köster 
Georg-August-University Göttingen, DE

Viola Vogel
ETH Zurich, CH

Stéphanie P. Lacour (tbc) 
EPF Lausanne, CH

Marcy Zenobi-Wong 
ETH Zurich, CH


Fred Zülli 
Mibelle Group, CH


Please also check our exhibitor list


Join us on Facebook


Share visions with
our speakers on YouTube


Follow us on Twitter
BIC 2020


BIC 2018

Join our Group on LinkedIn


Mark the week of August 16-19, 2021 in your agendas! Feel free to drop us your email address
and we'll provide more information.



This interdisciplinary and international conference is a unique opportunity

 to strengthen bridges between different disciplines of the life sciences do-
 main, particularly between the University Hospital Zurich and the Univer-
 sity of Zurich with the ETH.  In addition to the diversity of science and
 engineering, special emphasis will be laid on the gender-balanced educa-
 tion of students and early-career scientists, which encourages and
 allows them to emerge as independent scientists.

Prof. Beatrice Beck Schimmer,
Vice President Medicine, University Hospital Zurich


Contributed talks (20 min) will be assigned on the basis of submitted abstracts. There will be a large poster session, space for an industry exhibition, and many occasions for participants to meet, discuss, exchange ideas and find partners for future collaborations.

Given recent scientific, technological and translational progress across a range of fields likely to impact future societies, we have revisited the session topics for the 3rd BIC conference in 2021. (full list of topics: see below at the end):

Organoids, organs-on-chips and the growing understanding of how to physically interface biomaterials with various cell types hold great technological and societal promise, with applications in fields including tissue engineering, drug development and human toxicology. Important progress has been made most recently in approaches that are key to future translation and application of organ-like in vitro systems, such as cell sources, stem cell technology, 3D cell printing, and 3D high resolution imaging. Speakers will address status and future directions in these fields, also related to personalized medicine, and will also highlight the importance of involving all stakeholders - from academia, clinics, (pharmaceutical) companies and society at large – in translating personalized organs-on-chips to precision medicine.

These technologies also have the potential to reduce animal testing needs, but require further research, continued innovation and discussion in our society as clinical validation and translational maturity for many of these in vitro approaches remains unverified.

Neuronal Interfaces also hold great promise, given recent progress in identifying the intrinsic control architecture of brain networks. This will likely contribute to providing a fundamental basis for the exogenous control of brain networks and future progress in the Artificial Intelligence / Machine Learning field. Human-machine Interfacing is a key buzzword in this field, and biointerface technology a critical topic to enable its future progress.

As the program for the day is still under development, we will provide more information about the translational session in the future. For the time being, suggestions and further questions are welcome: please feel free to contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..


Sessions topics BIC-2021

Stem Cell Technology & Regenerative Medicine, Personalized Health, Gene Editing Technologies (e.g. CRISPR/Cas9) 

Organoids, Organ-on-Chip, Lab-on-Chip, 3D Imaging, Verification and Validation

3D Cell & Matrix Printing, Tissue Engineering


Nanoparticulate Systems for Diagnosis and Targeted Therapy incl. (Drug) Delivery Systems and Precision Medicine

Neuronal Interfaces, Bioelectronics and Biosensors

Artificial Intelligence, Machine Learning, Computational Modelling Approaches to Biomaterials,
Biointerfaces and Biomedical Processes

Functional Material-Biology Interfaces (to Tissue, Cells, Bacteria, Enzymes/Proteins, …),
Bioinspired Responsive Surfaces,
immuno-Modulatory Biointerfaces

Progress in Surface & Interface Characterization and Imaging (static/dynamic, in-situ and ex-situ),

Translational Challenges, Medical (MDR) & Regulatory Challenges




 Jeannette Wibmer